Physician profile
Sara Baumgartner
NPI 1043654361
$4,007.75
in general payments reported to CMS, 2019-2025
32 companies · $42.64 in 2025
The $42.64 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,333 · 2020: $119 · 2021: $299 · 2022: $444 · 2023: $381 · 2024: $389 · 2025: $42.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $813.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $813.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,231.27 | 2019-2022 | |
| Aspira Women'S Health INC | $275.92 | 2021-2024 | Ova1 |
| Abbvie INC. | $246.25 | 2020-2023 | Lo Loestrin Fe, Liletta |
| Bayer Healthcare Pharmaceuticals INC. | $161.48 | 2019-2024 | |
| Hologic Sales and Service, LLC | $110.52 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $100.40 | 2020-2024 | Gardasil 9, Gardasil |
| Exeltis, USA INC. | $93.63 | 2022-2025 | Slynd |
| Therapeuticsmd, INC. | $83.70 | 2019-2022 | |
| Laborie Medical Technologies Corp. | $63.00 | 2023 | |
| Pfizer INC. | $60.52 | 2021-2023 | |
| Coopersurgical, INC. | $57.84 | 2019-2023 | Paragard T 380a |
| Sumitomo Pharma America, INC. | $56.03 | 2023-2024 | Myfembree |
| Myovant Sciences INC. | $51.97 | 2021-2022 | |
| Lupin INC. | $47.37 | 2019-2021 | |
| Organon LLC | $46.88 | 2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $40.80 | 2024 | Veozah |
| Boston Scientific Corporation | $24.42 | 2023 | Watchman Access System |
| Agile Therapeutics, INC. | $23.66 | 2021 | |
| Mayne Pharma Commercial LLC | $22.63 | 2023 | |
| Acelrx Pharmaceuticals, INC. | $22.48 | 2021 | |
| Biogen, INC. | $21.81 | 2025 | Zurzuvae |
| Gynesonics, INC. | $19.64 | 2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Convatec INC. | $17.54 | 2022 | |
| Becton, Dickinson and Company | $17.12 | 2024 | Bd Onclarity |
| Daiichi Sankyo INC. | $17.04 | 2019 | |
| Davol INC. | $15.40 | 2024 | Arista Ah Flexitip |
| Molnlycke Health Care US, LLC | $15.25 | 2024 | Mepilex Border Post-Op Ag |
| Amag Pharmaceuticals, INC. | $14.55 | 2019 | |
| Channel Medsystems, INC. | $12.84 | 2023 | |
| Minerva Surgical, INC | $12.46 | 2019 | |
| Ethicon US, LLC | $12.30 | 2019 | |
| Duchesnay USA Incorporated | $11.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Baumgartner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.